Marseilles
France
61
2023-03-30
61
2026-04-07
These are the the leading inventors for applications assigned to INNATE PHARMA:
INNATE PHARMA based in Marseilles, FR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
TREATMENT OF CANCER
#2 | 2023-01-26 ✅ Patent 12,202,907 granted on 2025-01-21Nucleic acids encoding and methods of producing proteins comprising antibody chains
#3 | 2022-10-27 ✅ Patent 12,365,731 granted on 2025-07-22NKp46 BINDING AGENTS
#4 | 2022-02-10 ✅ Patent 12,528,876 granted on 2026-01-20CD73 BLOCKING ANTIBODIES
#5 | 2021-11-25 ✅ Patent 12,084,498 granted on 2024-09-10Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#6 | 2021-11-18 ✅ Patent 12,448,442 granted on 2025-10-21TREATMENT OF T CELL LYMPHOMA
#7 | 2021-11-04 ✅ Patent 12,227,569 granted on 2025-02-18Humanized antibodies with increased stability
#8 | 2021-09-02 ✅ Patent 11,891,444 granted on 2024-02-06Variable regions for NKp46 binding proteins
#9 | 2021-08-19 ✅ Patent 12,209,126 granted on 2025-01-28Treatment of cancer
#10 | 2021-08-05 ✅ Patent 12,037,392 granted on 2024-07-16Treatment regimens using anti-NKG2A antibodies
#11 | 2021-03-25 ✅ Patent 11,970,535 granted on 2024-04-30Treatment with anti-KIR3DL2 agents
#12 | 2021-03-04 ✅ Patent 11,795,222 granted on 2023-10-24Treatment of head and neck cancer
#13 | 2020-12-17 ✅ Patent 11,958,907 granted on 2024-04-16CD73 blockade
#14 | 2020-11-26 ✅ Patent 11,623,954 granted on 2023-04-11Siglec-9-neutralizing antibodies
#15 | 2020-11-26 ✅ Patent 11,447,545 granted on 2022-09-20Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
#16 | 2020-10-22 ✅ Patent 11,572,410 granted on 2023-02-07Neutralization of inhibitory pathways in lymphocytes
#17 | 2020-06-25 ✅ Patent 11,858,990 granted on 2024-01-02KIR3DL2 binding agents
#18 | 2020-04-30 ✅ Patent 11,845,795 granted on 2023-12-19NKp46 binding proteins
#19 | 2020-01-23 ✅ Patent 11,377,503 granted on 2022-07-05Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
#20 | 2019-12-26 ✅ Patent 11,578,136 granted on 2023-02-14Compositions and methods for treating cancer
#21 | 2019-12-05 ✅ Patent 11,377,492 granted on 2022-07-05NKp46 binding agents
#22 | 2019-10-24 ✅ Patent 11,225,519 granted on 2022-01-18Treatment of cancers using anti-NKG2A agents
#23 | 2019-10-17 ✅ Patent 11,999,784 granted on 2024-06-04Treatment of peripheral T cell lymphoma
#24 | 2019-09-12 ✅ Patent 11,066,470 granted on 2021-07-20Humanized antibodies with increased stability
#25 | 2019-07-25 ✅ Patent 11,130,817 granted on 2021-09-28CD73 blocking agents
#26 | 2019-05-02 ✅ Patent 11,078,275 granted on 2021-08-03Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#27 | 2019-03-21 ✅ Patent 11,078,274 granted on 2021-08-03Siglec neutralizing antibodies
#28 | 2019-02-21 ✅ Patent 12,252,543 granted on 2025-03-18Multispecific NK engager protein
#29 | 2019-02-14 ✅ Patent 11,267,897 granted on 2022-03-08Multispecific NK engager protein
#30 | 2019-01-31 ✅ Patent 10,870,700 granted on 2020-12-22Neutralization of inhibitory pathways in lymphocytes
#31 | 2018-12-27 ✅ Patent 10,736,963 granted on 2020-08-11Methods for detecting tissue infiltrating NK cells
#32 | 2018-12-13 ✅ Patent 11,001,629 granted on 2021-05-11Variable regions for NKp46 binding proteins
#33 | 2018-12-06 ✅ Patent 11,083,785 granted on 2021-08-10Siglec-10 antibodies
#34 | 2018-08-23 ✅ Patent 10,766,966 granted on 2020-09-08CD73 blockade
#35 | 2018-08-02 ✅ Patent 11,365,393 granted on 2022-06-21Compositions and methods for regulating NK cell activity
#36 | 2018-07-12 ✅ Patent 10,675,359 granted on 2020-06-09Enzymatic conjugation of antibodies
#37 | 2018-05-03 ✅ Patent 10,688,180 granted on 2020-06-23Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
#38 | 2017-11-02 ✅ Patent 10,329,348 granted on 2019-06-25Treatment of cancers using anti-NKG2A agents
#39 | 2017-10-19 ✅ Patent 10,174,112 granted on 2019-01-08Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
#40 | 2017-10-19 ✅ Patent 10,676,523 granted on 2020-06-09Treatment regimens using anti-NKG2A antibodies
#41 | 2017-10-12 ✅ Patent 10,711,063 granted on 2020-07-14Neutralization of inhibitory pathways in lymphocytes
#42 | 2017-07-27 ✅ Patent 11,208,480 granted on 2021-12-28Multispecific antigen binding proteins
#43 | 2017-07-13 ✅ Patent 10,519,234 granted on 2019-12-31NKp46 binding proteins
#44 | 2017-06-08 ✅ Patent 10,280,222 granted on 2019-05-07Humanized antibodies with increased stability
#45 | 2016-12-22 ✅ Patent 10,113,003 granted on 2018-10-30Multispecific NK engager proteins
#46 | 2016-11-17 ✅ Patent 10,434,180 granted on 2019-10-08Enzymatic conjugation of polypeptides
#47 | 2016-09-08 ✅ Patent 10,494,433 granted on 2019-12-03Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
#48 | 2016-04-28 ✅ Patent 10,071,169 granted on 2018-09-11Enzymatic conjugation of polypeptides
#49 | 2016-02-18 ✅ Patent 9,828,427 granted on 2017-11-28Anti-KIR3D antibodies
#50 | 2016-01-28 ✅ Patent 10,611,824 granted on 2020-04-07Solid phase TGase-mediated conjugation of antibodies
#51 | 2015-12-31 ✅ Patent 10,344,087 granted on 2019-07-09Treatment of peripheral T cell lymphoma
#52 | 2015-12-03 ✅ Patent 10,132,799 granted on 2018-11-20Screening of conjugated antibodies
#53 | 2015-10-15 ✅ Patent 10,246,510 granted on 2019-04-02KIR3DL2 binding agents
#54 | 2015-10-08 ✅ Patent 10,036,010 granted on 2018-07-31Recognition tags for TGase-mediated conjugation
#55 | 2015-10-08 ✅ Patent 9,789,182 granted on 2017-10-17Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
#56 | 2015-08-20 ✅ Patent 10,577,419 granted on 2020-03-03KIR3DL2 binding agents
#57 | 2014-12-04 ✅ Patent 9,764,038 granted on 2017-09-19Enzymatic conjugation of antibodies
#58 | 2012-03-15 ✅ Patent 9,181,341 granted on 2015-11-10Anti-KIR3D antibodies
#59 | 2012-02-09 ✅ Patent 9,388,246 granted on 2016-07-12TLR3 binding agents
#60 | 2011-10-06 ✅ Patent 8,735,624 granted on 2014-05-27Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same
#61 | 2006-07-11 ✅ Patent 7,074,409 granted on 2006-07-11Polypeptides having a triggering NK activity and biological applications
Also check out INNATE PHARMA's (Marseilles, France) applicant profile with 62 patent applications submitted.
349026 ⎘